Pharvaris (NASDAQ:PHVS) President Peng Lu Sells 15,000 Shares

Pharvaris N.V. (NASDAQ:PHVS) President Peng Lu sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $40.68, for a total transaction of $610,200.00. Following the sale, the president directly owned 65,179 shares in the company, valued at $2,651,481.72. The trade was a 18.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Peng Lu also recently made the following trade(s):

• On Thursday, June 18th, Peng Lu sold 300 shares of Pharvaris stock. The shares were sold at an average price of $34.00, for a total transaction of $10,200.00.

Pharvaris Stock Performance

Shares of NASDAQ:PHVS opened at $37.74 on Thursday. Pharvaris N.V. has a 52 week low of $20.65 and a 52 week high of $43.25. The firm has a market cap of $2.47 billion, a PE ratio of -12.37 and a beta of -2.33. The firm’s fifty day moving average is $34.93 and its 200-day moving average is $31.27.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). Sell-side analysts forecast that Pharvaris N.V. will post -3.15 EPS for the current year.

Hedge Funds Weigh In On Pharvaris

Several institutional investors have recently added to or reduced their stakes in PHVS. venBio Partners LLC bought a new position in shares of Pharvaris during the 2nd quarter worth approximately $160,569,809. Wellington Management Group LLP acquired a new position in shares of Pharvaris during the 3rd quarter valued at $43,282,000. 5AM Venture Management LLC bought a new position in Pharvaris during the second quarter worth $27,581,008. California State Teachers Retirement System grew its holdings in Pharvaris by 3,210.1% in the second quarter. California State Teachers Retirement System now owns 799,490 shares of the company’s stock worth $27,646,000 after purchasing an additional 775,337 shares during the period. Finally, Paradigm Biocapital Advisors LP increased its stake in Pharvaris by 72.7% in the third quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company’s stock valued at $45,796,000 after purchasing an additional 772,583 shares in the last quarter.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Rosenblatt Securities set a $60.00 target price on Pharvaris in a report on Wednesday. Citigroup restated a “market outperform” rating on shares of Pharvaris in a research report on Wednesday. Guggenheim upped their price objective on shares of Pharvaris from $39.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, August 13th. Wells Fargo & Company increased their price objective on shares of Pharvaris from $55.00 to $65.00 and gave the stock an “overweight” rating in a research report on Wednesday. Finally, Morgan Stanley lifted their target price on shares of Pharvaris from $46.00 to $62.00 and gave the stock an “overweight” rating in a research note on Wednesday. Twelve investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $59.21.

Trending Headlines about Pharvaris

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Pharvaris reported that its pivotal Phase 3 CHAPTER-3 trial of extended-release deucrictibant met its primary and all secondary efficacy endpoints, showing statistically significant and clinically meaningful prevention of HAE attacks. The results are intended to support regulatory applications planned to begin in the first half of 2027. Pharvaris CHAPTER-3 topline data
• Positive Sentiment: The CHAPTER-3 success, combined with earlier positive Phase 3 results for on-demand deucrictibant, strengthens Pharvaris’ potential to offer oral options for both prevention and treatment of HAE attacks. Analysts said the data could help the company capture market share in the HAE market. Pharvaris could gain HAE market share
• Positive Sentiment: RBC raised its price target to $62 from $52 and maintained an Outperform rating, while Citizens JMP increased its target to $79 from $75 with a Market Outperform rating. HC Wainwright also reaffirmed Buy with a $60 target, indicating broad analyst confidence in the program’s commercial potential.
• Positive Sentiment: A Seeking Alpha analysis maintained a “Strong Buy” view, citing the Phase 3 wins and the upcoming regulatory decision, or PDUFA event, for deucrictibant. Pharvaris Strong Buy analysis
• Neutral Sentiment: Despite the favorable data, Pharvaris remains a clinical-stage company. Regulatory approval, commercial execution, and the ability to compete with existing HAE therapies remain important uncertainties; RBC continued to characterize the stock as carrying speculative risk.
• Negative Sentiment: President Peng Lu sold 15,000 shares for approximately $610,200, reducing his direct ownership by 18.71%. The transaction may create a modest overhang, although it does not change the clinical outlook.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.